ArticleBMC nephrology2026
Elevated cardiometabolic index is associated with an increased risk of cardiovascular and all-cause mortality in patients undergoing dialysis: a retrospective cohort study.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundFew studies have explored the relationship between cardiometabolic index (CMI) and the risk of death from dialysis. This study aimed to investigates whether the CMI values correlates with cardiovascular and all-cause mortality in patients undergoing dialysis. The study population included patients undergoing maintenance hemodialysis (MHD) and maintenance peritoneal dialysis (MPD).
methodThis retrospective cohort study included patients undergoing dialysis (MHD and MPD) from January 2022 to and June 2025. Patients were divided into tertiles based on the CMI measured at the start of follow-up. Restricted Cubic Splines (RCS) were used to model the association between elevated CMI and the risk of adverse outcomes. The Kaplan-Meier curve was used to compare survival differences among the three groups. Additionally, a subgroup analysis identified and confirmed the risk factors.
resultsA total of 551 patients were included in this study. The risks of cardiovascular and all-cause mortality increased gradually across the CMI tertiles (13%, 19%, and 35% for cardiovascular mortality; 15%, 27%, and 50% for all-cause mortality; trend p < 0.001). RCS analysis was used to evaluate the association between elevated CMI and the risk of adverse outcomes. As CMI increased, the risk of all-cause mortality showed a significant increase (hazard ratio [HR] = 2.16, p < 0.001), as did the risk of cardiovascular mortality (HR = 1.82, p < 0.001) among all dialysis patients. After adjusting for various potential confounders, CMI remained a risk factor for cardiovascular and all-cause mortality among patients undergoing dialysis.
conclusionIncreased CMI was positively correlated with a higher risk of cardiovascular mortality and all-cause mortality in patients undergoing dialysis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.